Cyclic AMP signaling in cardiac myocytes by Leroy, Jérôme et al.
HAL Id: hal-02471410
https://hal.archives-ouvertes.fr/hal-02471410
Submitted on 8 Feb 2020
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Cyclic AMP signaling in cardiac myocytes
Jérôme Leroy, Grégoire Vandecasteele, Rodolphe Fischmeister
To cite this version:
Jérôme Leroy, Grégoire Vandecasteele, Rodolphe Fischmeister. Cyclic AMP signaling in cardiac my-
ocytes. Current Opinion in Physiology, Elsevier, 2018, 1, pp.161-171. ￿10.1016/j.cophys.2017.11.004￿.
￿hal-02471410￿
COPHYS-D-17-00014-Revised                                                              1 
 
Cyclic AMP signaling in cardiac myocytes 
 
Jérôme Leroy, Grégoire Vandecasteele and Rodolphe Fischmeister 
 
INSERM UMR-S 1180, Univ Paris-Sud, Université Paris-Saclay,  
Châtenay-Malabry, France 
 
 
 
 
 
 
 
 
Correspondence to:  
Rodolphe Fischmeister 
UMR-S 1180 
Faculté de Pharmacie 
Université Paris-Sud 
5 rue J-B Clément 
92296 Châtenay-Malabry 
France.  
rodolphe.fischmeister@inserm.fr 
Tel: +33-1.46.83.57.71; Fax: +33-1.46.83.54.75 
 
  
COPHYS-D-17-00014-Revised                                                              2 
 
Abstract 
The cyclic nucleotide 3’, 5‘-cyclic adenosine monophosphate (cAMP) is a ubiquitous 
second messenger of paramount importance in the regulation of the cardiac pump. It is 
now well established that cAMP is confined in specific subcellular compartments where 
it modulates various targets associated in signalosomes to control e.g. excitation-
contraction coupling or gene transcription. In this review, we summarize notable 
breakthroughs on how cAMP is synthesized, degraded and compartmentalized. We 
describe its effectors, including newly described targets with emerging roles in heart. We 
also briefly discuss innovative methods recently developed to bring new insights on the 
role of these cAMP microdomains to control cardiac function. 
 
Introduction 
Since the discovery 60 years ago of the cyclic nucleotide cyclic adenosine 3′,5′-
monophosphate (cAMP) many questions arouse and many answers were given on how 
this second messenger controls cardiac function. The sympathetic nerve/β-adrenergic 
receptor (β-AR)/adenylyl cyclase (AC)/cAMP/protein kinase A (PKA) axis is the 
canonical route to stimulate cardiac rhythm (chronotropy), contractile force (inotropy) 
and relaxation (lusitropy) [1]. PKA phosphorylates many of the proteins critically involved 
in the excitation contraction coupling (ECC). These include the L-type Ca2+ channels 
(LTCCs) [2] to increase the amplitude of ICa,L, the ryanodine receptor 2 (RyR2) [3] to 
increase its opening, phospholamban (PLB) to relieve its inhibitory effect on the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2) [4] and contractile proteins, such 
as troponin I (TnI) and myosin binding protein C, to accelerate cardiac relaxation [1]. 
Additionally, PKA phosphorylates the phosphatase 1 inhibitor [5], β-AR receptors and 
phosphodiesterases (PDEs) [6] to modulate intracellular signaling pathways that control 
not only ECC but also gene transcription, apoptosis and cell survival, and thus cardiac 
remodeling. While PKA is a major target for cAMP, the cyclic nucleotide also acts 
independently of the kinase binding directly to various proteins. The aim of the present 
review is not to be exhaustive, but to give an overview of the current knowledge on 
cAMP pathways in cardiac cells and discuss new perspectives in the field.  
cAMP synthesis 
All seven transmembrane receptors coupled to heterotrimeric G proteins (GPCRs) 
driving cAMP production do not lead to similar functional effects, but activate specifically 
localized effectors comforting the hypothesis of a compartmentation of cAMP signals [6]. 
The localization of the enzymes (ACs) which catalyze the conversion of ATP to cAMP 
and pyrophosphate is also determinant for the spatial organization of these signals. The 
main sources of cAMP in the cardiomyocytes are transarcolemmal ACs which are 
activated by Gαs freed upon GPCR activation by catecholamines and various hormones. 
Among the nine known AC isoforms, AC5 and AC6 are the main enzymes expressed in 
heart [7]. While both enzymes share 65% homology and are activated by Gαs, but 
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inhibited by Gαi, PKA and Ca2+, extensive investigations led to the general conclusion 
that both enzymes have diametrically opposite roles in heart [8]. This could be due to 
their differential localization: AC5 is present in the nuclear envelop [9,10] and in 
caveolin-3 domains of the T-tubule membrane and is coupled to β1- and β2-ARs [11]; 
AC6 is expressed in the plasma membrane outside the T-tubular system and is coupled 
to β1-ARs only [11]. However, the expression of β2-ARs in myocytes was recently 
challenged in mouse heart [12]. The difference in the intrinsic enzymatic activities of 
AC5 and AC6 or their different modulation by PKC-dependent phosphorylation could 
also explain some of their functional differences [8]. AC5 deletion resulted in either 
enhanced or unaltered contractile performances and decreased sensitivity or blunted 
maximal response to β-AR stimulation [13-15]. AC6 KO animals exhibit reduced left 
ventricular contractile function and relaxation [13]. Interestingly, AC5 deletion increases 
longevity due to increased antioxidant capacities [16], improves exercise performance 
[17] and protects the heart against catecholamine infusion and pressure overload 
[15,18]. Similarly, AC6 KO mice are also protected against pressure overload [19]. 
However, the major difference between the two isoforms is that cardiac overexpression 
of AC5 leads to an impaired heart function [20] and exacerbates the cardiomyopathy 
induced by chronic catecholamine stress [21], whereas overexpression of the AC6 
isoform improves heart function in murine cardiomyopathy due to Gαq overexpression 
[22]. Furthermore, AC5 inhibition prevents heart failure (HF) induced by myocardial 
infarction or by chronic catecholamine stress in mice, and protects against myocardial 
apoptosis [23] and myocardial ischemia in mice and swine [24]. Gene transfer of AC6 
confirmed its beneficial effects since it increased left ventricular (LV) function and 
attenuated deleterious LV remodeling in a pig model of HF [25]. This paved the way to 
gene therapy with AC6 in HF patients, and a recent randomized clinical trial 
demonstrated improved LV function after intracoronary delivery of an adenovirus 
encoding AC6 in HF, with most benefits in patients with nonischemic etiology [26●]. 
However, larger trials are warranted to confirm these positive outcomes. 
A cardiac role for soluble AC (sAC), which is activated by bicarbonate and Ca2+ and is 
insensitive to G proteins, has recently began to emerge. Its presence within the 
mitochondria has been suggested to regulate oxidative phosphorylation. In neonatal 
cardiomyocytes, mitochondrial cAMP production measured using a fluorescence 
resonance energy transfer (FRET) biosensor follows Ca2+ oscillation in the cytosol 
suggesting that these organelles can integrate an oscillatory Ca2+ signal to increase 
cAMP in their matrix [27]. This was confirmed by our group which demonstrated a 
protective role for sAC against cell death, apoptosis as well as necrosis [28●]. Upon 
stimulation with bicarbonate and Ca2+ of isolated mitochondria, sAC produces cAMP, 
which in turn stimulates oxygen consumption, increases the mitochondrial membrane 
potential and ATP production giving further evidences of sAC in the organelles [28●]. 
However, cAMP analogues failed to alter mitochondrial respiration in mitochondria from 
pig hearts in another study [29]. Thus, cAMP signaling within the matrix remains 
controversial [30] and further studies are required to confirm the role of sAC in the 
mitochondria. 
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cAMP targets in heart 
Among cAMP receptors, PKA is a major player in the cAMP signaling pathways in heart. 
Two general classes of PKA are expressed, named PKA-I and PKA-II, due to 
differences in their regulatory (R) subunits, respectively RI and RII. Two R subunits 
dimerize and each associates with two catalytic (C) subunits to form holoenzymes. PKA-
RI is mainly cytosolic while PKA-RII associates with the particulate fraction [31,32] and 
with key proteins of the ECC, and is considered as the main isoform responsible for the 
inotropic effects of a β-AR stimulation. PKA also phosphorylates the endogenous 
inhibitor of phosphatase 1 (I-1), causing inhibition of the enzyme which acts as a distal 
amplifier of β-AR signaling [5]. The role of PKA-RI in heart remains elusive. However, 
overexpression of a microARN, mir-208a, decreased RI expression and the β-AR 
inotropic effects, suggesting a potential role for this isoform to control ECC [33●]. PKA 
activation occurs when two cAMP molecules bind to each R subunit. This allows a 
conformational change leading to the dissociation of the C subunit. However, this dogma 
has been recently challenged by the discovery of disordered and flexible regions within 
RII bound to A kinase anchoring proteins (AKAPs) that determine how far from the 
AKAP the C region can operate and define the efficiency of the binding of the kinase to 
its target [34●●]. Further evidences confirmed that AKAPs constrain C subunits that 
operate within a radius of 200 Å but dissociate when cAMP reaches supraphysiological 
levels allowing it to reach nuclear targets [35]. This model of static C subunits 
orchestrating the phosphorylation of peculiar substrates nicely fits the rapid and specific 
PKA-RII phosphorylation of the key proteins of the ECC. It also explains the slow 
kinetics of PKA activation in the nucleus despite equivalently rapid elevations of 
cytosolic and nuclear cAMP levels [36,37]. It is well known that high catecholamine 
concentrations and prolonged β-AR stimulation, unlike brief β-AR agonist applications, 
can lead to PKA phosphorylation of transcription factors of the cAMP response element 
(CRE)-Binding protein (CREB) family [36,37] to induce cardiac hypertrophy. Increased 
phosphorylation/activation of CREB is an important factor in the up-regulation of ICER 
(inducible cAMP early repressor) expression which inhibits the antiapoptotic BCL-2 
expression [38]. BCL-2 and the dynamin related protein 1 (Drp1) are both PKA 
substrates suggesting that PKA may regulate not only apoptosis but also mitochondria 
dynamics [39●]. Indeed, mitochondrial cAMP-PKA signaling cascade was found to 
control mitochondria elongation and mitochondrial cell-death [30]. However, the 
presence of PKA within the matrix [28●] or at the membrane of the organelle [30] is 
under debate. Additionally, PKA may control gene transcription via other nuclear 
proteins such as Class II histone deacetylases (HDACs) [40-42]. β-ARs can also 
activate the signal transducer and activator of transcription 3 (STAT3), which is critical 
for the transcription of β-AR signaling components including receptors, PKA and Ca2+ 
channels [43]. PKA can also exert cardioprotective effects via the phosphorylation of 
Hsp20 [44]. 
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Besides activating PKA, cAMP binds to, and modulates the gating of, the 
hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel HCN4, the main 
isoform expressed in the sinus node, the atrioventricular node and Purkinje fibers, 
leading to positive chronotropic and dromotropic effects [45].  
Epac (Exchange Protein directly Activated by cAMP) proteins are other important cAMP 
effectors in heart [46]. Initially, Epac was found to affect Ca2+ homeostasis in neonatal 
cardiomyocytes [47] and this was then confirmed in adult cells, where Epac, 
downstream of the β-AR, leads to SR Ca2+ leak by activating Ca2+/Calmodulin kinase II 
(CaMKII) which phosphorylates RyR2 [48] and PLB [49] via a sequential activation of 
Rap, PLCε, and PKCε [50,51]. To do so, one Epac isoform (Epac2) is localized in the Z 
striation of the cardiomyocyte [52,53]. However, an alternative pathway has been 
recently proposed which involves a β1-AR/Epac/PI3K/Akt/NOSynthase1/CaMKII 
cascade [54]. Epac also exerts pro-arrhythmic effects by its ability to decrease 
potassium currents [55]. Moreover, inotropic effects of Epac activation by increasing 
myofilament Ca2+ sensitivity were reported [56]. Epac1, the second isoform expressed in 
heart, is localized around the nucleus [52], suggesting a role in controlling nuclear 
function. Accordingly, chronic Epac activation leads to cardiac hypertrophy [47,57] by 
initiating HDAC5 nuclear export and subsequent activation of MEF2 [58]. Epac 
downregulates the subunit of the potassium voltage-gated channel subfamily E member 
1 (KCNE1) [59] and increases TRPC3/4 channel expression [60]. Furthermore, Epac1 
activation also leads to autophagy activity in response to chronic activation of β-AR [61]. 
Epac1 might also be expressed within mitochondria where its activation by cAMP 
generated by sAC would protect mitochondria from Ca2+ overload and cell death [28●]. 
However, another recent study demonstrated that invalidation of Epac1 reduces infarct 
size and cardiomyocyte apoptosis induced by myocardial ischemia/reperfusion injury 
[62●]. Thus, like for the mitochondrial cAMP/PKA signaling pathway, future studies are 
warranted to fully understand the functional role of cAMP/Epac1 in this organelle.  
In the early 2000’s, a fourth class of cAMP effector encoded by Popeye domain 
containing (Popdc) genes with domains resembling the secondary structure of the 
cAMP-binding domain of the R subunit of PKA-II was discovered [63●●]. Of the three 
known Popdc genes (1-3) [64], Popdc1 and 2 are highly expressed in cardiac tissue, 
especially in the conduction system including the sinus and atrioventricular nodes 
[63●●]. While no cardiac hypertrophy nor ECG modification was noticed in KO animals 
for the two genes, these mice exhibited bradycardia under mental stress or β-AR 
stimulation in an age dependent manner [63●●]. Interestingly, patients with a Popdc1 
mutation display early onset AV-block arrhythmias [65]. To influence pacemaker activity 
and electric conduction, Popdc interacts with the potassium channel TREK-1 to increase 
its expression at the plasma membrane, thus enhances K+ current density, both 
phenomena being negatively modulated by cAMP [63●●]. Popdc interacts with caveolin 
3 within caveolae in the T-tubules [66]. The number of binding partners of Popdc is 
increasing and the presence of the protein at the nuclear envelope suggests a role in 
transcriptional activity [65]. Indubitably, new functions for Popdc proteins in heart will be 
discovered in the near future. 
COPHYS-D-17-00014-Revised                                                              6 
 
cAMP elimination from cardiomyocytes 
cAMP synthesis is counterbalanced by elimination processes to terminate the activation 
of cAMP effectors. This is mostly achieved by phosphodiesterases (PDEs) which 
specifically cleave the 3′,5′-cyclic phosphate moiety of cAMP to produce 5′-AMP. PDEs 
share conserved catalytic domains but differ markedly in their N-domains which contain 
diverse elements allowing their dimerization, binding of regulatory small molecules, 
phosphorylation and localization. Among the eleven known PDE families, five are 
expressed in heart to degrade cAMP: PDE1, which is activated by Ca2+-calmodulin, 
PDE2, which is activated by cGMP, and PDE3, which is inhibited by cGMP, degrade 
both cGMP and cAMP while PDE4 and PDE8 are specific for cAMP. Each family can be 
encoded by several genes which together generate a multitude of PDE isoforms by the 
use of different translation initiation sites and alternative mRNA splicing. Extensive work 
to delineate the role in cardiac cells of these various enzymes has been performed, that 
is described in details in various reviews [6,67-69]. 
Despite its high level of expression in human and rodent cardiomyocytes [70,71], the 
functional role of PDE1 in myocytes is poorly documented. However, simultaneous 
measurements of Ca2+ signals and cAMP levels in paced cardiomyocytes demonstrated 
a role for PDE1 in shaping cAMP signals in a Ca2+ dependent manner to control ECC 
[72●]. Two isoforms of PDE1, PDE1A and C are expressed in heart [71]. Inhibition or 
genetic downregulation of PDE1A was found to prevent hypertrophy induced by various 
neurohumoral stimuli via a cGMP/PKG rather than cAMP mechanism [71]. PDE1C 
deficiency or inhibition attenuated apoptosis, in a cAMP/PKA and PI3K/AKT dependent 
manner in vitro and its genetic deletion attenuated cardiac remodeling and dysfunction 
induced by transverse aortic constriction in mice [73]. Accordingly, vinpocetine, a PDE1 
inhibitor, prevented myocyte hypertrophy, fibroblast activation by TGF-β and fibrotic 
gene expression thus pathological remodeling induced by chronic stimulation with 
angiotensin II [74], confirming that PDE1 activation contributes to pathological cardiac 
remodeling.  
Recently, PDE2 gained a lot of attention. PDE2 represents a minor part of total cAMP 
hydrolytic activity at basal, but its cAMP hydrolytic activity is stimulated up to 30-fold by 
cGMP. PDE2 was shown to inhibit cardiac LTCC in various species, including humans 
[6] and measurements with FRET-based sensors showed that PDE2 counteracts the 
effects of β-AR stimulation downstream of β3-ARs [75]. In contrast to PDE3 and PDE4 
which expression and activity are generally decreased in pathological hypertrophy and 
HF [76-78], PDE2 is increased in animal models as well as in human HF and this blunts 
β-AR/cAMP signals suggesting a protective mechanism against increased circulating 
catecholamines [79]. Accordingly, PDE2 overexpression improves cardiac function after 
myocardial infarction and protects against catecholamine-induced arrhythmias [80●●]. 
However, conflicting results were reported showing that PDE2 exerts prohypertrophic 
effects by blunting PKA-mediated phosphorylation of nuclear factor of activated T cells 
(NFAT) [81●●]. Furthermore, PDE2 inhibition was found to exert cardioprotective effects, 
resulting in elongated mitochondria and protecting against apoptotic cell death [30] and 
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improving mitochondrial respiration in sepsis induced myocardial dysfunction [82]. To do 
so, PDE2 would be part of a cAMP/PKA signaling domain at the surface of the organelle 
[30]. Whether PDE2 activation or inhibition produces cardioprotective effects is therefore 
a matter of debate [83,84] that will be probably arbitrated by ongoing studies.  
PDE3 and PDE4 are the main PDE families controlling cAMP and ECC in heart. While 
PDE3 prevails in human and large mammal cardiac tissue [85], PDE4 dominates to 
control cAMP produced upon β-AR stimulation to control ECC in rodents [86,87], but 
also regulates cAMP levels and Ca2+ homeostasis in human atria and in dog 
cardiomyocytes [88,89]. PDE3 is encoded by two genes, pde3A and pde3B. PDE3A is 
responsible for the inotropic and chronotropic effects of PDE3 inhibitors. Because it 
associates with PLB in a phosphorylation-dependent manner [90], PDE3A controls 
SERCA2 activity and Ca2+ reuptake in the SR [91]. Furthermore, PDE3A is associated 
with myocyte apoptosis, likely through sustained induction of ICER [92], leading to the 
hypothesis that its overexpression may limit cardiac damages. Accordingly, 
overexpression of this isoform prevents ischemia/reperfusion (I/R)-induced myocardial 
infarction [93].  
The PDE4 family is encoded by four genes (pde4a–d). Most of our knowledge of the 
roles of individual PDE4 subtypes in the heart is limited to PDE4D. It was found to 
regulate the PKA phosphorylation of RyR2 and its invalidation promotes sensitivity to 
ventricular arrhythmias and late-onset dilated cardiomyopathy [77]. PDE4D is crucial for 
the control of Ca2+ homeostasis in atria and its expression is decreased in atrial 
fibrillation [88], a cause of stroke. Interestingly, single nucleotide polymorphism (SNPs) 
in the pde4d gene were shown to be associated with cardiogenic shock [94] and 
cardioembolism [95] further suggesting its importance in the control of sinus rhythm. 
Similarly to PDE3A, PDE4D also associates with the PLB/SERCA2 complex and 
regulates SR Ca2+ load in the mouse heart [96,97]. It also controls the slowly activating 
delayed rectifier potassium channels [98], the desensitization of β1- and β2-ARs, 
associating either directly or indirectly through β-arrestin with the receptors [99-101]. 
PDE4D also degrades cAMP signals at the perinuclear region to regulate cardiac 
hypertrophy [102]. Lately, PDE4B was identified as an integral component of the LTCC 
complex to control ICa,L during β-AR stimulation [97]. PDE4B KO mice exhibit an 
increased susceptibility to ventricular arrhythmias upon catecholamine stimulation, 
probably linked to enhanced ICa,L [97]. Although RyR2 phosphorylation by PKA did not 
seem to be affected in adult PDE4B KO mice [97], a recent study indicated that it is 
increased in neonatal PDE4B KO myocytes [103], suggesting that altered RyR2 
regulation may also contribute to these arrhythmias. Recently, we showed that under β-
AR stimulation, inhibition of PDE4 (as well as inhibition of PDE3) exerted inotropic 
effects via PKA but led to spontaneous diastolic Ca2+ waves via both PKA and CaMKII, 
suggesting the potential use of CaMKII inhibitors as adjuncts to PDE inhibitors to limit 
their proarrhythmic effects [104]. 
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PDE8A is also expressed in cardiomyocytes and its invalidation leads to exacerbated β-
AR stimulation of the ECC and perturbation of the Ca2+ homeostasis [105]. However, 
further studies are required to fully understand the role of PDE8A in heart. 
While hydrolysis by PDEs represents the main process to eliminate cAMP produced 
upon neurohormonal stimulations, there is also a contribution of nucleotide efflux from 
the cardiomyocyte. This is achieved by multidrug-resistance proteins (MRPs), of which 
the MRP4 isoform is crucial for cAMP homeostasis, since Mrp4 KO mice exhibit 
enhanced cAMP and contractility and develop cardiac hypertrophy with age [106]. 
 
cAMP compartmentation in cardiomyocytes 
The first evidence for a compartmentation of cAMP signaling in heart came from 
experiments showing that upon β-AR stimulation, cAMP and force of contraction were 
enhanced and soluble and particulate PKA activated, while upon PGE1 application, no 
change in contractile activity was observed despite an increase in cAMP and activation 
of soluble PKA [32,107]. Since then, a tremendous amount of work allowed to 
demonstrate that cAMP signaling is compartmentalized within the cardiomyocyte 
[6,8,69]. Different localizations of receptors and ACs are partly responsible for this 
compartmentation. Differentially localized β1- and β2-AR, AC5 and AC6 to caveolar T-
tubular domains vs. non caveolar domains [11,108] and sAC in the mitochondria [28●] 
constitute various production sites in discrete membrane domains leading to the 
activation of cAMP effectors in close vicinity. Furthermore, it has been recently 
suggested that mitochondria act as physical barriers to limit cAMP diffusion in 
cardiomyocytes [109,110] and that association of PKA-RII at the surface of the organelle 
may play a crucial role in the limitation of cAMP diffusion [110]. Local specificity in cAMP 
functions is also achieved by the specific localization of its effectors. AKAPs, by 
localizing PKA in close proximity to its substrates play an essential role [111]. For 
example, PKA-RII was found associated with LTCC via the short AKAP7 (AKAP18α) 
[112], with RyR2 via mAKAP (AKAP6) [113], with SERCA2A complex via the long 
AKAP7 (AKAP18δ) [114], and with KCNQ1 [115]. By coordinating signaling pathways, 
AKAPs are crucial to achieved localized temporal regulation of β-AR stimulation. This is 
further attested by arrhythmias associated with mutations or SNPs in the yotiao gene 
associated with long QT [116,117]. PKA is not the sole cAMP effector found in 
macromecular complexes; for example, Epac1 was also found together with PKA, ERK5 
and PDE4D tethered by the AKAP6 at the nuclear envelop to control cardiac 
hypertrophy [102]. Over the past 30 years, PDEs have been described as essential 
players in the compartmentation of cAMP [6,67,69]. Associated in macromolecular 
complexes, PDEs control cAMP levels at the vicinity of cAMP effectors such as the key 
ECC proteins as discussed earlier. Their role in limiting cAMP emanation from β-AR-
stimulated AC was first demonstrated in cardiac cells studying the impact of PDE 
inhibition on ICa,L regulation by local application of isoprenaline, suggesting their role as 
enzymatic barrier limiting cAMP diffusion [118]. Until then, only biochemical methods 
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involving cell fractionation gave a rough idea of cAMP signaling compartmentation 
[32,107]. Later, overexpression of exogenous mutant CNG channels allowed indirect 
cAMP measurements but limited at the subsarcolemmal compartment [87,119]. The 
advent of FRET bisosensors based on Epac [120], PKA [121], or PKA substrates [122] 
allowed to directly visualize cAMP concentration changes [123]. New technologies and 
the development of new biosensors permits now cAMP measurements in microdomains. 
Epac1-based sensors fused with the regulatory subunits of PKA-RI or PKA-RII allowed 
to visualize the differential cAMP increase induced by either β-AR stimulation or PGE1 
in RII and RI compartments, respectively [124]. More recently, a sophisticated approach 
combining SCIM and FRET-imaging demonstrated the functional distribution of β-ARs 
subtypes in crests and T-tubules, taking advantage of the glass pipette used for cell 
surface topography measurements to locally and selectively activate β1- or β2-ARs [108]. 
A move towards cAMP measurements within “nanodomains” has been made by fusing 
sensors based on Epac1 or on the cAMP binding domain of the RII subunit of PKA with 
specific peptide sequences allowing their targeting at the membrane [125], in lipid rafts 
or non-rafts domains [126], to compartments including key multiprotein complexes 
involved in ECC such as SERCA2 protein [127,128●], TnI [128●], and the LTCC 
complex [125,128●]. Furthermore, combining genetic animal models overexpressing an 
Epac1-based biosensor with a stereomicroscope system recently allowed to measure 
cAMP changes directly in perfused heart in more physiological conditions [129●●]. 
Undoubtedly, in the near future, all these new approaches will provide exciting new 
insights concerning the organization of cAMP nanodomains within the cardiomyocyte 
and their functional roles. 
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Figure Legend 
 
Figure 1: The cartoon shows the differential cAMP signaling pathways and the 
localization of the various signalosomes in the cardiomyocyte including newly described 
transduction cAMP signals in the mitochondria. sAC, soluble adenylate cyclase; AC, 
adenylyl cyclase; AKAP, A-kinase anchoring protein; CaMKII, Ca2+-Calmodulin kinase II; 
β-AR, β-adrenergic receptors. 
 
Table 1: Physiological role of key players in the cAMP signalling pathways in heart and known implications in cardiac 
diseases. 
Actors of cAMP signaling 
in cardiomyocytes 
isoforms Physiological roles Known implications in cardiac diseases 
AC5  cAMP synthesis upon β2-AR stimulation [11] Increased expression in HF [130] 
AC6  cAMP synthesis upon β1-AR stimulation [11] Decreased expression in HF [130] 
sAC  Regulation of oxidative stress, increase in 
mitochondrial respiration [27,28●] (but see 
[29]) 
Cardioprotective against cell death, 
apoptosis and necrosis [28●] 
Short AKAP7 (AKAP18α)  Association of PKA-RII with LTCC [112]  
Long AKAP7 (AKAP18δ)  Association of PKA-RII with SERCA2A [114]  
AKAP6 (mAKAP)  - Association of PKA-RII with RyR2 and 
PDE4D [113] 
- Association of PKA-RII, Epac1, ERK5 and 
PDE4D at the nuclear envelope [102] 
Coordinates signalling pathways leading to 
hypertrophy and cardiac remodelling [111] 
AKAP9 (Yotiao)  Association of PKA-RII with KCNQ1 [115] - Decreased interaction with PKA-RII in 
dilated cardiomyopathy [131] 
- SNPs associated with long QT [117] 
PKA PKA-RI Control of ECC [33●] - Antihypertrophic effects via NFAT 
phosphorylation [81●●] 
- Apoptosis via BCL-2 phosphorylation 
[39●] 
- Cardioprotective effects via Hsp20 [44] 
- Gene transcription/hypertrophic signals 
via phosphorylation of CREB [36,37], 
STAT3 [43], HDAC [40-42], BCL-2 [38] 
- Ca2+ homeostasis 
perturbations/arrhythmias [104] 
PKA-RII - Phosphorylation of key proteins of ECC 
[32] 
- Phosphorylation of PDEs to increase 
cAMP hydrolysis [87,119] 
- Phosphorylation of the phosphatase 
inhibitor-1 [5] 
EPAC Epac1 
 
- Excitation-transcription coupling [58] 
 
- Increased expression in HF [57] 
- Hypertrophy [47,57] 
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Epac2 - Activation of CaMKII leading to RyR2 and 
PLB phosphorylation [48-51,55] 
- Regulation of Ca2+ sensitivity of 
myofilaments [56] 
- Autophagy [61] 
- Apoptosis [28●,62●] 
- Diminishes KCNE1 expression [59] 
- Increases TRPC3/4 expression [60] 
- Ca2+ homeostasis 
perturbations/arrhythmias [53] 
Popdc1 and 2  Pacemaker/electrical conductivity by 
enhancing TREK1 functional expression 
[63●●] 
AV block associated with popdc1 mutation 
[65] 
PDE1  Control of ECC [70] - Hypertrophy [71] 
- Apoptosis [73] 
- Fibrotic gene expression [74] 
PDE2  Control of ECC [6,79] - Increased expression in heart failure [79] 
- Pro-hypertrophic [81●●] or 
antihypertrophic [79] 
- Apoptosis [39●] 
- Mitochondrial respiration in sepsis [82] 
PDE3  - Control of ECC [87,90] 
- PLB phosphorylation [90,91] 
- Decreased expression in hypertrophy 
[76] 
- Prevents Ca2+ homeostasis 
perturbations/arrhythmias [91,104] 
- Apoptosis [92,93] 
PDE4  - Control of ECC 
- PKA phosphorylation of PLB, RyR2, LTCC 
and KCNQ1 [77,96,97,103,104] 
- β-AR desensitization [99,100] 
- Decreased expression in hypertrophy 
[76], heart failure [77] and atrial fibrillation 
[88] 
- Prevents Ca2+ homeostasis 
perturbations/arrhythmias [77,88,104] 
- Hypertrophy [101,102] 
- SNPs in Pde4d gene associated with 
cardiogenic stroke [94] and 
cardioembolism [95] 
PDE8  Control of ECC [105]  
MRP4  cAMP extrusion [106]  
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